CANDONI, ANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.108
AS - Asia 15.240
EU - Europa 7.355
SA - Sud America 1.709
Continente sconosciuto - Info sul continente non disponibili 402
AF - Africa 233
OC - Oceania 44
Totale 43.091
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.501
CN - Cina 5.278
SG - Singapore 4.046
IT - Italia 2.561
HK - Hong Kong 1.790
GB - Regno Unito 1.426
BR - Brasile 1.333
KR - Corea 979
VN - Vietnam 961
BD - Bangladesh 926
FI - Finlandia 897
RU - Federazione Russa 408
DE - Germania 401
FR - Francia 355
SE - Svezia 349
CA - Canada 263
IN - India 258
ID - Indonesia 253
NL - Olanda 218
LT - Lituania 148
JP - Giappone 133
AR - Argentina 130
MX - Messico 119
TR - Turchia 117
UA - Ucraina 114
IQ - Iraq 102
IE - Irlanda 75
AT - Austria 65
EC - Ecuador 60
ZA - Sudafrica 56
AE - Emirati Arabi Uniti 53
CO - Colombia 52
PK - Pakistan 48
BG - Bulgaria 46
ES - Italia 46
CR - Costa Rica 43
AU - Australia 42
PL - Polonia 40
CZ - Repubblica Ceca 39
JM - Giamaica 39
VE - Venezuela 37
SA - Arabia Saudita 31
CL - Cile 30
UZ - Uzbekistan 28
TN - Tunisia 27
KE - Kenya 26
MA - Marocco 26
EG - Egitto 25
PY - Paraguay 25
MY - Malesia 24
TW - Taiwan 24
IL - Israele 23
TT - Trinidad e Tobago 23
TH - Thailandia 21
PH - Filippine 20
NP - Nepal 19
GT - Guatemala 18
DZ - Algeria 17
PT - Portogallo 17
CH - Svizzera 16
HN - Honduras 16
NI - Nicaragua 16
UY - Uruguay 16
PE - Perù 15
SC - Seychelles 15
BE - Belgio 14
JO - Giordania 14
RO - Romania 14
OM - Oman 13
EE - Estonia 12
SV - El Salvador 12
BY - Bielorussia 11
DK - Danimarca 11
DO - Repubblica Dominicana 11
BO - Bolivia 10
GR - Grecia 10
HR - Croazia 10
HU - Ungheria 10
PR - Porto Rico 10
AZ - Azerbaigian 9
KZ - Kazakistan 9
BB - Barbados 8
AL - Albania 7
PS - Palestinian Territory 7
SY - Repubblica araba siriana 7
AO - Angola 6
BS - Bahamas 6
EU - Europa 6
GP - Guadalupe 6
KG - Kirghizistan 6
QA - Qatar 6
SK - Slovacchia (Repubblica Slovacca) 6
CW - ???statistics.table.value.countryCode.CW??? 5
IR - Iran 5
MD - Moldavia 5
RS - Serbia 5
BA - Bosnia-Erzegovina 4
ET - Etiopia 4
LB - Libano 4
LV - Lettonia 4
Totale 42.612
Salva come PNG Salva come JPEG
Città #
Hefei 3.388
Ashburn 2.758
Singapore 2.435
Santa Clara 1.962
Hong Kong 1.690
San Jose 1.576
Council Bluffs 1.121
Seoul 972
Helsinki 816
London 700
Fairfield 513
The Dalles 454
Los Angeles 409
Southend 381
Milan 362
New York 356
Ho Chi Minh City 334
Beijing 327
Houston 301
Chicago 282
Woodbridge 262
Seattle 242
Lauterbourg 221
Rome 215
Dallas 211
Buffalo 210
Hanoi 208
Kent 197
Chandler 195
Nyköping 191
Jakarta 180
Wilmington 179
Boardman 163
Cambridge 160
São Paulo 159
Ann Arbor 158
Jacksonville 134
Moscow 115
Dearborn 114
Phoenix 108
San Diego 108
Columbus 107
Munich 107
North Bergen 104
Salt Lake City 99
Shanghai 96
Amsterdam 94
Atlanta 83
Redondo Beach 81
Modena 77
Bologna 75
Frankfurt am Main 73
Dublin 68
Brooklyn 64
Nuremberg 64
Reggio Emilia 63
Tokyo 63
Tampa 60
Mexico City 59
Washington 57
Elk Grove Village 55
Indianapolis 54
Da Nang 53
Naples 53
Delhi 52
Florence 52
Saint Augustine 51
Boston 50
Toronto 49
Miami 45
Montreal 45
Princeton 45
Turin 45
Guangzhou 44
Hillsboro 42
San Francisco 42
Rio de Janeiro 40
Sofia 40
Orem 39
Baghdad 38
Charlotte 38
Miano 38
Belo Horizonte 36
Newark 36
Izmir 35
Philadelphia 35
Brasília 32
Palermo 31
Detroit 30
Kilburn 30
Lappeenranta 30
Mumbai 30
Eugene 29
Warsaw 29
Lansdowne 28
Las Vegas 28
Shenzhen 27
Bari 26
Des Moines 26
Figino 26
Totale 27.915
Salva come PNG Salva come JPEG
Nome #
Characterization of Specific Immune Responses to Different Aspergillus Antigens during the Course of Invasive Aspergillosis in Hematologic Patients 460
Mucorales-specific T cells in patients with hematologic malignancies 393
A hematology consensus agreement on antifungal strategies for neutropenic patients with hematological malignancies and stem cell transplant recipients 379
All-trans retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase. 373
Anagrelide in Essential Thrombocythemia: A Retrospective Analysis of 220 Patients. Session Type: Poster Session 646-III 358
The Role of Wilms’ Tumor Gene (WT1) Expression as a Marker of Minimal Residual Disease in Acute Myeloid Leukemia 353
Peg Interferon alpha-2b (Peg Intron) in Essential Thrombocythemia 350
Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial 349
invasive aspergillosis in patients with acute myeloid leukemia: SEIFEM-2008 registry study. 347
Identification and characterization of Aspergillus-specific immune responses to diagnose invasive aspergillosis in high risk patients: a multicenter study 325
Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study) 321
PEG Intron in Essential Thrombocythemia: Two Years Treatment in 90 Patients. 315
Distribution of different classes of CSF3R mutations and co-mutational pattern in 360 myeloid neoplasia 294
European Study of Cerebral Aspergillosis treated with Isavuconazole (ESCAI): A study by the ESCMID Fungal Infection Study Group 292
Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia-like or acute lymphoblastic leukemia-like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study 291
Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers 288
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. 287
Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy 279
Mucorles-specific T cells emerge in the course of invasive mucormucosis and may be used as a surrogate diagnostic marker in high-risk patients 278
Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation 266
Adherence to international guidelines for the treatment of invasive aspergillosis in acute myeloid leukaemia: Feasibility and utility (SEIFEM-2008B study) 266
PEG Intron Treatment in 90 Patients with Essential Thrombocythemia (ET) Final Report of a Phase II Study. 254
Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations 253
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) 246
Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data 246
Bone Marrow Evaluation According to the PVSG and WHO Criteria in 90 Essential Thrombocythemia (ET) Patients Treated with PEG Interferon alpha-2b. Preliminary Results. 240
PEG Interferon a-2b (PEG-Intron) in Essential Thrombocythemia: Phase II Study for Determination of the Minimum Effective, Safe and Tolerated Dose. Preliminary Data. 240
Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation. Results from a multicenter survey 239
Prognostic Relevance of Multi-Antigenic Myeloma-Specific T-Cell Assay in Patients with Monoclonal Gammopathies 239
Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. 232
Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management 232
Pneumocystis jirovecii pneumonia at chest High-resolution Computed Tomography (HRCT)in non-HIV immunocompromised patients: Spectrum of findings and mimickers 229
Bone marrow biopsy and aspirate evaluation in 90 patients with Essential Thrombocythemia treated with PEG interferon alpha-2b. Preliminary results 226
10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG 225
Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use 223
Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with Venetoclax 222
Up-front Blinatumomab Improves MRD Clearance and Outcome in Adult Ph− B-lineage ALL: the GIMEMA LAL2317 Phase 2 Study 222
SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy 222
Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia 221
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 216
Early palliative care versus usual haematological care in multiple myeloma: retrospective cohort study 215
Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry. 215
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial 212
Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GINEMA infection program 212
Intravascular lymphoma: Clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant' 211
Characteristics and clinical behavior of acute myeloid leukemia harboring rare non-A/B/D nucleophosmin (NPM1) gene mutation subtypes: a single-center experience and review of the literature 211
PEG Interferon alpha2b (PEG Intron) in Essential Thrombocytemia: Phase II Study for Determination of the Minimun Effective, Safe and Tolerated Dose. Preliminary Data. 207
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia 206
Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience 204
Severe acute respiratory syndrome coronavirus 2 infection in patients with hematological malignancies in the Omicron era: Respiratory failure, need for mechanical ventilation and mortality in seronegative and seropositive patients 203
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 197
Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID-19: The GIMEMA EMATO-0321 study 195
Advanced mast cell disease: An Italian Hematological Multicenter experience 191
Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in "Real-Life": The SEIFEM Experience 187
Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: An Italian multicentre prospective survey 187
Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia 183
Acute myeloid leukemia in patients previously diagnosed with breast cancer: Experience of the GIMEMA group 182
Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial 180
COVID-19 omicron variant outbreak in a hematopoietic stem cell transplant unit 179
Neurological complications in adult allogeneic hematopoietic stem cell transplant patients: Incidence, characteristics and long-term follow-up in a multicenter series 177
Antibody Binding Capacity for Evaluation of MDR-Related Proteins in Acute Promyclocytic Leukemia: Onset Versus Relapse Expression 175
Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the SEIFEM-D registry 175
Abdominal abscess and Hafnia alvei septicemia occurring during the aplastic phase after autologous stem-cell transplantation in a patient with diffuse large B-cell lymphoma 173
'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study 172
Identification and validation of diagnostic cut-offs of the ELISpot assay for the diagnosis of invasive aspergillosis in high-risk patients 171
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: Retrospective analysis of 530 patients 170
Clinical impact of ceftazidime/avibactam on the treatment of suspected or proven infections in a large cohort of patients with haematological malignancies: a multicentre observational real-world study 170
Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia 168
Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1mut) for the Treatment of NPM1mut-Acute Myeloid Leukemia 168
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 168
Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy 165
Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial 165
Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial 164
High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission 164
Antiviral prophylaxis to prevent herpes simplex virus (HSV) and varicella zoster virus (VZV) reactivation in adult patients with newly diagnosed acute leukemia: results of a survey submitted to Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group 163
Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia 163
Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE) 162
Real-Time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: Results from a prospective, monocentric, interventional study 159
Antibody response to mRNA vaccination for COVID-19 in patients with AML receiving hypomethylating agents alone or with venetoclax 157
Ponatinib as a Prophylactic or Pre-Emptive Strategy to Prevent Cytological Relapse after Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Transplanted in Complete Cytological Remission 157
A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia 157
Upfront intensive treatment analysis of the Italian Cohort Study on FLT3‐mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real‐life setting 157
Systemic antifungal treatment after posaconazole prophylaxis: Results from the SEIFEM 2010-C survey 156
Reduced prophylactic effect of tixagevimab-cilgavimab in patients with hematological malignancies and without antibody response after SARS-COV-2 vaccination 156
FLAI induction regimen in elderly patients with acute myeloid leukemia 155
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph1 acute lymphoblastic leukemia 155
Multicentre survey to explore current survival of patients with acute myeloid leukaemia who failed induction chemotherapy 155
Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study 154
Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease 154
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias 153
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 153
ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol 152
Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy 151
Invasive aspergillosis in relapsed/refractory acute myeloid leukaemia patients: Results from SEIFEM 2016-B survey 151
Early Palliative Care, Goals of Care Conversations and Quality EOL Care in Acute Leukemia and HR-MDS 150
Fungaemia in haematological malignancies: SEIFEM-2015 survey 150
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO) 149
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts 149
Chronic Obstructive Pulmonary Disease and Previous Infections Have Impact on Infectious Complications in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax: A Multicentre Seifem Study 146
A GIMEMA survey on therapeutic use and response rates of FLT3 inhibitors in acute myeloid leukemia: Insights from Italian real‐world practice 145
Totale 21.622
Salva come PNG Salva come JPEG
Categoria #
all - tutte 212.711
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 212.711
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022487 0 0 0 0 30 57 34 42 87 52 90 95
2022/20231.245 79 47 43 53 88 87 319 130 200 28 72 99
2023/20242.253 58 67 144 201 370 187 325 230 54 65 223 329
2024/20259.165 218 117 96 624 1.549 1.063 390 347 1.016 886 1.539 1.320
2025/202620.269 1.801 1.492 2.461 2.005 1.240 1.267 2.716 854 1.550 1.661 1.641 1.581
2026/20276.688 854 1.399 1.703 2.498 234 0 0 0 0 0 0 0
Totale 43.091